Company Profile We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
CARLSBAD, Calif., June 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Corporate presentation at its 2015 Annual Meeting of Stockholders
Tuesday, June 30 at 5:10 p.m. ET / 2:10 p.m. PT
Live on the Internet. Simply log onto our website listed above.
CARLSBAD, Calif., June 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has been added to the Russell 1000 Index, effective June 26, 2015. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.
"We are pleased to be added to this impo...
Continued increases observed in multiple measures of muscle function in SMA children treated with ISIS-SMN Rx
CARLSBAD, Calif., June 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx and are continuing to receive treatment in an open-label extension (OLE) study. Consistent with earlier observations, increases in muscle function...
CARLSBAD, Calif., June 16, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2015 Annual Meeting of Stockholders and Open House on Tuesday, June 30 at 2:10 p.m. Pacific Time in Carlsbad, CA.
The agenda for the meeting is as follows:
2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of May 4, 2015)